Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
Head Neck. 2021 Jan;43(1):392-406. doi: 10.1002/hed.26492. Epub 2020 Oct 17.
We conducted the current systemic review to provide up-to-date literature summary and optimal evidence-based recommendations for ipsilateral radiation for squamous cell carcinoma of the tonsil.
We performed literature search of peer-reviewed journals through PubMed. The search strategy and subject-specific keywords were developed based on the expert panel's consensus. Articles published from January 2000 to May 2020 with full text available on PubMed and restricted to the English language and human subjects were included. Several prespecified search terms were used to identify relevant publications and additional evidence published since the initial American College of Radiology Appropriateness Criteria Ipsilateral Tonsil Radiation recommendation was finalized in 2012. The full bibliographies of identified articles were reviewed and irrelevant studies were removed.
The initial search and review returned 46 citations. The authors added three citations from bibliographies, websites, or books not found in the literature search. Of the 49 citations, 30 citations were retained for further detailed review, and 14 of them were added to the evidence table. Articles were removed from the bibliography if they were not relevant or generalizable to the topic, or focused on unknown primary disease. Several commonly encountered clinical case variants were created and panelists anonymously rated each treatment recommendation. The results were reviewed and disagreements discussed.
The panel provided updated evidence and recommendations for ipsilateral radiation for squamous cell carcinoma of the tonsil in the setting of primary radiation-based therapy and postoperative adjuvant radiotherapy. This committee did not reach agreements for some case variants due to a lack of strong evidence supporting specific treatment decisions, indicating a further need for research in these topics.
我们进行了本次系统评价，旨在为扁桃体鳞状细胞癌同侧放疗提供最新的文献总结和最佳循证推荐。
我们通过 PubMed 对同行评审期刊进行了文献检索。该搜索策略和主题特定关键字是根据专家小组的共识制定的。纳入标准为 2000 年 1 月至 2020 年 5 月发表的全文可获取的 PubMed 上的英语文献和以人为研究对象的文献。使用了几个预设的检索词来识别相关出版物，并纳入了自 2012 年美国放射学院（ACR）同侧扁桃体放疗推荐最终确定以来发表的额外证据。还对已确定文章的全文进行了综述，并排除了不相关的研究。
最初的搜索和综述共返回了 46 篇引用。作者从文献检索中未找到的文献、网站或书籍中添加了 3 篇引用。在这 49 篇引用中，有 30 篇被保留下来进行进一步详细审查，其中有 14 篇被添加到证据表中。如果文章与主题不相关或不可推广，或者侧重于未知的原发性疾病，则会从参考文献中删除。创建了几个常见的临床病例变体，然后小组成员匿名对每个治疗建议进行评分。对结果进行了审查和讨论。
专家组针对原发性放疗和术后辅助放疗时扁桃体鳞状细胞癌同侧放疗提供了更新的证据和推荐。由于缺乏支持特定治疗决策的有力证据，该委员会未能就某些病例变体达成一致意见，这表明在这些主题上还需要进一步的研究。
